Table 1

Baseline Characteristics of Patients, Overall and According to Subgroups of LVEF

VariableOverall
(N = 824)
HeFrEF
(LVEF ≤35%)
(n = 202, 25%)
36% ≤ LVEF <50%
(Intermediate LVEF)
(n = 252, 31%)
HeFnEF
(LVEF ≥50%)
(n = 370, 45%)
Missing Values
Age, yrs74 ± 1173 ± 1073 ± 1076 ± 110
Sex555 (67%)159 (79%)185 (73%)211 (57%)0
IHD455 (55%)140 (69%)157 (62%)158 (43%)0
NYHA functional class
 I228 (28%)58 (29%)78 (31%)92 (25%)0
 II423 (51%)99 (49%)122 (48%)202 (55%)0
 III172 (21%)44 (22%)52 (21%)76 (21%)0
 IV1 (0.1%)1 (1%)000
BMI, kg/m229 (25–33)27 (24–31)29 (25–33)29 (25–34)22
HR, beats/min71 ± 1370 ± 1271 ± 1471 ± 1416
Sinus rhythm517 (63%)142 (70%)171 (68%)204 (55%)0
HR if SR68 ± 1268 ± 1268 ± 1269 ± 1311
AF307 (37%)60 (30%)81 (32%)166 (45%)0
HR if AF75 ± 1474 ± 1276 ± 1575 ± 155
SBP, mm Hg133 ± 24126 ± 23131 ± 24139 ± 2417
Hypertension, SBP >140 mm Hg272 (34%)47 (24%)73 (29%)152 (43%)17
LVEF, %44 ± 1129 ± 541 ± 454 ± 50
NT-proBNP, ng/l1,002 (367–2,151)1,349 (551–2,945)929 (339–1,997)920 (321–1,874)59
 NT-proBNP if in SR569 (246–1,519)1008 (412–2,573)607 (249–1,319)399 (202–990)37
 NT-proBNP if not inSR1667 (1,047–2,984)2008 (1,181–3,405)1618 (971–2,705)1557 (1,091–2,880)22
eGFR, ml/min52 (37–71)51 (36–66)54 (37–71)53 (37–72)41
BiV pacing92 (11%)53 (27%)26 (10%)13 (4%)4
Loop diuretic609 (74%)167 (83%)174 (69%)268 (73%)1
BB701 (85%)189 (94%)226 (90%)286 (78%)2
 ≥100% of guideline BB dose187 (23%)64 (32%)61 (24%)62 (17%)2
 ≥50% of guideline BB dose413 (50%)122 (60%)129 (51%)162 (44%)2
ACE-I/ARB698 (85%)186 (92%)227 (90%)285 (77%)1
MRA385 (47%)131 (65%)136 (54%)118 (32%)1
Ivabradine23 (3%)8 (4%)8 (3%)7 (2%)0

Values are mean ± SD, n (%), or median (interquartile range).

ACE-I = angiotensin-converting enzyme inhibitor; AF = atrial fibrillation/flutter; ARB = angiotensin receptor blocker; BB = beta-blocker; BMI = body mass index; BiV = biventricular; eGFR = estimated glomerular filtration rate; HeFnEF = heart failure with normal ejection fraction; HeFrEF = heart failure with reduced ejection fraction; HR = heart rate; IHD = ischemic heart disease; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association; NT-proBNP = N-terminal pro–B-type natriuretic peptide; SBP = systolic blood pressure; SR = sinus rhythm.